Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

n 2008 compared to 2007. The increase in these expenses is expected to arise from continued enrollment and continued re-treatments in our existing clinical trials.

Pre-Clinical Trial Expenses and Research Collaborations

2008 2007

$ $

-------------------------------------------------------------------------

Research collaboration expenses - 106,281

Pre-clinical trial expenses - -

-------------------------------------------------------------------------

Pre-clinical trial expenses and research

collaborations - 106,281

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the first quarter of 2008, our research collaboration activity focused on renewing specific collaborations, but no costs were incurred compared to $106,281 for the first quarter of 2007. Our research collaboration activity continues to focus on the interaction of the immune system and the reovirus and the use of the reovirus as a co-therapy with existing chemotherapeutics and radiation.

We still expect that our pre-clinical trial expenses and research collaborations in 2008 will remain consistent with 2007.

Other Research and Development Expenses

2008 2007

$ $

-------------------------------------------------------------------------

R&D consulting fees 27,408 91,776

R&D salaries and benefits 478,118 372,389

Other R&D expenses
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and ... of revenue. The Automatic patient billing market in Asia ... 2018, at a developing CAGR of 7.2% from 2013 ... Asian Automatic patient billing market, to get an idea ... glimpse of the segmentation of this market in the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... HUNTINGTON BEACH, California and AMSTERDAM, September ... today announced the,successful closing of a US $23 million ... undisclosed family investment firm that provided,approximately half of the ... of US $1 million each, while the remaining,capital was ...
... , ATLANTA, Sept. 22 The International ... Rose Associates has joined its global network. IESF is the ... welcome Sanford Rose Associates (SRA) as one of its global ... offices primarily located throughout the USA will considerably enhance IESF,s ...
... , , PRINCETON, N.J., Sept. 22 ... clinical development services to innovative pharmaceutical, biotechnology, generic drug ... Brennan has joined the Company as general counsel. , ... have Chris join the PharmaNet Development Group management team," ...
Cached Biology Technology:Agendia Raises US $23 Million in Series E Financing 2Sanford Rose Associates Joins the International Executive Search Federation 2Christopher Brennan Joins PharmaNet Development Group as General Counsel 2
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... 2004, Washington University in St. Lous researcher Jianmin Cui was ... channel his lab had been studying for five years. ... a large family whose members suffered from epilepsy, sudden attacks ... and paroxysmal dyskinesia (GEPD). By analyzing the DNA of ...
... attacks in the United States are fostering development of ... to protect people against the potentially deadly bacteria in ... sweeping overview of scientific research on medical technology to ... Journal of Medicinal Chemistry . In ...
... are reporting that particle size affects the toxicity of zinc ... 100 nanometers are slightly more toxic to colon cells than ... equivalent amounts of soluble zinc, and direct particle to cell ... in ACS, Chemical Research in Toxicology , a monthly ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
...
DTT 50 l...
...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: